[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 44 of about 44
1. Lehmann C, Wyen C, Hoffmann C, Fätkenheuer G: Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma. HIV Med; 2005 Jan;6(1):51-3
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma.
  • Treatment of AIDS-related malignant lymphoma (ARL) remains a therapeutic challenge.
  • We report the case of a 38-year-old man with advanced HIV-1 infection, pulmonary tuberculosis and Burkitt's lymphoma.
  • Six months later, the patient achieved not only a complete remission of Burkitt's lymphoma and sustained viral suppression, but also a full recovery from tuberculosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Antitubercular Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] AIDS-Related Opportunistic Infections / complications. AIDS-Related Opportunistic Infections / drug therapy. Adult. Humans. Male. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670254.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


2. Oriol A, Ribera JM, Brunet S, del Potro E, Abella E, Esteve J: Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica; 2005 Jul;90(7):990-2
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.
  • Short, intensive cycles of chemotherapy have resulted in improved survival in BurkittOs lymphoma/leukemia (BL) in adults.
  • The prognosis of patients with immunodeficiency virus (HIV)-associated BL is considered to be poor, but these patients have seldom been treated with BL-specific protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Leukemia / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Aged. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dexamethasone / therapeutic use. Disease-Free Survival. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Prednisone / therapeutic use. Treatment Outcome. Vincristine / therapeutic use


3. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, Mbulaiteye SM: AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? Blood; 2010 Dec 16;116(25):5600-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?
  • Trimodal or bimodal age-specific incidence rates for Burkitt lymphoma (BL) were observed in the United States general population, but the role of immunosuppression could not be excluded.
  • Incidence rates, rate ratios, and 95% confidence intervals for BL and other non-Hodgkin lymphoma (NHL), by age and CD4 lymphocyte count categories, were estimated using Poisson regression models using data from the United States HIV/AIDS Cancer Match study (1980-2005).
  • BL incidence was 22 cases per 100 000 person-years and 586 for non-BL NHL.
  • Adjusted BL incidence rate ratio among males was 1.6× that among females and among non-Hispanic blacks, 0.4× that among non-Hispanic whites, but unrelated to HIV-transmission category.
  • Non-BL NHL incidence increased from childhood to adulthood; in contrast, 2 age-specific incidence peaks during the pediatric and adult/geriatric years were observed for BL.
  • Non-BL NHL incidence rose steadily with decreasing CD4 lymphocyte counts; in contrast, BL incidence was lowest among people with ≤ 50 CD4 lymphocytes/μL versus those with ≥ 250 CD4 lymphocytes/μL (incidence rate ratio 0.3 [95% confidence interval = 0.2-0.6]).
  • The bimodal peaks for BL, in contrast to non-BL NHL, suggest effects of noncumulative risk factors at different ages.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1124 [10025990.001]
  • [Cites] Cancer. 1957 Sep-Oct;10(5):1045-54 [13472655.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Oncologist. 2006 Apr;11(4):375-83 [16614233.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):589-92 [16741494.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Immunity. 2007 Aug;27(2):190-202 [17723214.001]
  • [Cites] AIDS. 2007 Nov 12;21(17):2265-70 [18090274.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2658-63 [18767045.001]
  • [Cites] Int J Cancer. 2009 Apr 1;124(7):1497-502 [19089924.001]
  • [Cites] Int J Cancer. 2009 Apr 15;124(8):1745-55 [19165855.001]
  • [Cites] Curr Opin HIV AIDS. 2009 May;4(3):183-7 [19532048.001]
  • [Cites] PLoS Med. 2009 Jul 7;6(7):e1000107 [19582166.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]
  • [Cites] Semin Cancer Biol. 2009 Dec;19(6):347-50 [19607918.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1732-9 [19810101.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Am J Med. 2001 Dec 15;111(9):704-11 [11747850.001]
  • [Cites] Ann Intern Med. 1969 Apr;70(4):817-32 [4306129.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18470-6 [10373455.001]
  • [Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]
  • [Cites] Eur J Cancer. 1972 Jun;8(3):305-8 [4677829.001]
  • [Cites] J Natl Cancer Inst. 1974 May;52(5):1397-401 [4406651.001]
  • [Cites] IARC Sci Publ. 1985;(60):217-24 [4065946.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Dec 25;36 Suppl 7:1S-20S [2826984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9838-42 [1682922.001]
  • [Cites] Nature. 1993 Mar 25;362(6418):355-8 [8455722.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Stat Med. 1995 Mar 15-Apr 15;14(5-7):491-8 [7792443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6577-81 [7604036.001]
  • [Cites] Prev Med. 1995 Jul;24(4):375-7 [7479628.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [CommentIn] Blood. 2010 Dec 16;116(25):5435-6 [21163931.001]
  • (PMID = 20813897.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CP / N02CP31003; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3031406
  •  go-up   go-down


Advertisement
4. Corti M, Villafañe MF, Souto L, Schtirbu R, Narbaitz M, Soler Mde D: Burkitt's lymphoma of the duodenum in a patient with AIDS. Rev Soc Bras Med Trop; 2007 May-Jun;40(3):338-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of the duodenum in a patient with AIDS.
  • Non-Hodgkin's lymphoma of B-cell type is the second most common neoplasm after Kaposi's sarcoma, among patients with human immunodeficiency virus infection.
  • Most non-Hodgkin's lymphoma cases that are associated with acquired immunodeficiency syndrome involve extranodal sites, especially the digestive tract and the central nervous system.
  • We report a case of primary lymphoma of the duodenum in a patient with AIDS.
  • A complete diagnostic study including histological, immunohistochemical and virological analyses showed high-grade B-cell Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Duodenal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653472.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


5. Giacinti C, Giordano A: RB and cell cycle progression. Oncogene; 2006 Aug 28;25(38):5220-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RB and cell cycle progression.
  • The Rb protein is a tumor suppressor, which plays a pivotal role in the negative control of the cell cycle and in tumor progression.
  • It has been shown that Rb protein (pRb) is responsible for a major G1 checkpoint, blocking S-phase entry and cell growth.
  • Loss of pRb functions may induce cell cycle deregulation and so lead to a malignant phenotype.
  • Functional inactivation of pRb by viral oncoprotein binding is also shown in many neoplasias such as cervical cancer, mesothelioma and AIDS-related Burkitt's lymphoma.
  • [MeSH-major] Cell Cycle / genetics. Retinoblastoma Protein / genetics
  • [MeSH-minor] Cell Division / genetics. Chromosome Mapping. Chromosomes, Human, Pair 13. Genes, Tumor Suppressor. Humans. Transcription, Genetic. Tumor Suppressor Proteins / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936740.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 86
  •  go-up   go-down


6. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM: AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol; 2005 Jul 1;23(19):4430-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
  • PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.
  • PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).
  • RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis.
  • Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Nov 20;23(33):8538-40; author reply 8540-1 [16293885.001]
  • [CommentIn] J Clin Oncol. 2005 Nov 1;23(31):8132-3; author reply 8133-4 [16258119.001]
  • (PMID = 15883411.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; M-BACOD protocol
  •  go-up   go-down


7. Couitchéré GL, Niangué-Beugré NM, Effi B, Ankotché A, Cissé L, Enoh J, Andoh J: [AIDS-related Burkitt's lymphoma in a black African child]. Arch Pediatr; 2005 Apr;12(4):473-4
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS-related Burkitt's lymphoma in a black African child].
  • [Transliterated title] Lymphome de Burkitt VIH-induit chez un enfant noir africain.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808442.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down


8. Kaaya EE, Castaños-Velez E, Ekman M, Mwakigonja A, Carneiro P, Lema L, Kitinya J, Linde A, Biberfeld P: AIDS and non AIDS-related malignant lymphoma in Tanzania. Afr Health Sci; 2006 Jun;6(2):69-75
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS and non AIDS-related malignant lymphoma in Tanzania.
  • BACKGROUND: Malignant lymphoma (ML) in HIV patients, are second in frequency to Kaposi's sarcoma (AKS) as AIDS-defining tumors.
  • In Africa the frequency of AIDS-related lymphoma (ARL) is rare and the findings are controversial.
  • Kaposi's sarcoma (KS) lesions are now causally associated with KSHV/HHV-8 but whether African ARL shows this association is not clear.
  • Both retrospective and prospective lymphoma cases were classified according to the revised European-American (REAL) classification.
  • OBJECTIVES: To determine the frequency and type of AIDS and non-AIDS related malignant lymphoma in Tanzania and a possible co-association with KSHV/HHV-8 and EBV.
  • The tumors were classified as Burkitt's (6), diffuse large cell (10), precursor-B lymphoblastic (1) and Hodgkin's disease (5) from HIV positive and negative patients.
  • Ten (40%) high grade ML and three Hodgkin's lymphoma from HIV patients had HHV-8 DNA.
  • These findings were not related to age, sex or type of lymphoma.
  • There was no association of HHV-8 with the lymphoma cells.
  • CONCLUSIONS: This study suggests an overall increased frequency of ML patients infected with HHV-8 in Tanzania particularly in HIV patients which may result from the well established high HHV-8 prevalence in the general population, but HHV-8 was not associated with ARL pathogenesis as reflected by lack of tumor cell infection.
  • [MeSH-major] Lymphoma / epidemiology. Lymphoma / pathology. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Developing Countries. Female. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. In Situ Hybridization. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Polymerase Chain Reaction. Registries. Retrospective Studies. Risk Assessment. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / pathology. Sarcoma, Kaposi / virology. Survival Analysis. Tanzania / epidemiology. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):79-88 [9709308.001]
  • [Cites] Br J Cancer. 1997;75(11):1704-7 [9184191.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 [16091217.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Scand J Infect Dis. 1994;26(6):749-52 [7747100.001]
  • [Cites] Int J Cancer. 1995 May 16;61(4):574-9 [7759163.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Nov 1;10(3):295-305 [7552491.001]
  • [Cites] AIDS. 2002 Mar 8;16(4):597-603 [11873003.001]
  • [Cites] J Med Virol. 2002 Oct;68(2):264-7 [12210417.001]
  • [Cites] Lancet Oncol. 2003 Feb;4(2):110-9 [12573353.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):375-405 [15129649.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] N Engl J Med. 1985 Dec 19;313(25):1564-71 [2999595.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):272-3 [8532016.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):202-4 [8546554.001]
  • [Cites] Br J Haematol. 1995 Dec;91(4):918-20 [8547139.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):221-9 [8607449.001]
  • [Cites] Blood. 1996 May 1;87(9):3903-9 [8611719.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] J Mol Med (Berl). 1995 Dec;73(12):603-9 [8825757.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] J Virol. 1997 Mar;71(3):2505-11 [9032391.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • (PMID = 16916294.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831982
  •  go-up   go-down


9. Singh AS, Dave DJ, Thanvi S, Atre DA, Parikh P, Patel NH: Fatal secondary pulmonary hypertension due to cardiac involvement in AIDS-associated Burkitt's lymphoma. Indian J Med Sci; 2006 Sep;60(9):380-4
MedlinePlus Health Information. consumer health - Pulmonary Hypertension.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal secondary pulmonary hypertension due to cardiac involvement in AIDS-associated Burkitt's lymphoma.
  • Primary cardiac lymphomas are rare lesions in children with acquired immunodeficiency syndrome (AIDS).
  • Most of them are high-grade Burkitt's or Burkitt-like lymphomas.
  • The clinical profile and operative and pathological findings of a 4-year-old boy with AIDS-associated Burkitt's lymphoma of the heart presenting with acute right heart failure and fatal secondary pulmonary hypertension is reported.
  • [MeSH-major] Burkitt Lymphoma / complications. Heart Neoplasms / complications. Hypertension, Pulmonary / etiology. Lymphoma, AIDS-Related / complications


10. Just PA, Fieschi C, Baillet G, Galicier L, Oksenhendler E, Moretti JL: 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS; 2008 Sep;22(9):695-700
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma.
  • This study aims to describe 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) findings in patients with AIDS-related Burkitt lymphoma, at various times of treatment, and to define its utility for a better patient management.
  • We retrospectively studied 13 consecutive HIV-positive patients with Burkitt lymphoma who underwent one or more PET/CT.
  • Lymph node involvement, which is known to be uncommon in endemic or sporadic Burkitt lymphoma, was present in 54% of patients.
  • Additionally, in 3 patients, Burkitt lymphoma was predominantly located in parotid lymph nodes, which is also an unusual finding.
  • A negative scan was encountered in 3 of 10 patients imaged during treatment and in 1 of 4 patients imaged after treatment completion and was always associated with lasting complete remission.
  • Presence of residual area of uptake was related to both favorable and unfavorable outcome whether performed during treatment (5/7 and 2/7, respectively) or after (1/3 and 2/3, respectively).
  • Areas of increased uptake could be observed in lung (4 cases) or esophagus (3 cases), and were clinically related to pneumonia or esophagitis.
  • We recommend PET/CT for accurate initial staging of patients with AIDS-related Burkitt lymphoma.
  • Furthermore, PET/CT appears to have prognostic value, as a negative scan was always associated with a favorable outcome.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Fluorodeoxyglucose F18. Lymphoma, AIDS-Related / diagnosis. Radiopharmaceuticals

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793085.001).
  • [ISSN] 1557-7449
  • [Journal-full-title] AIDS patient care and STDs
  • [ISO-abbreviation] AIDS Patient Care STDS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


11. Magrath I: Lessons from clinical trials in African Burkitt lymphoma. Curr Opin Oncol; 2009 Sep;21(5):462-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from clinical trials in African Burkitt lymphoma.
  • PURPOSE OF REVIEW: The center of gravity of the AIDS epidemic has moved - in 2007, 67% of all persons living with HIV infection and 72% of all deaths from AIDS occurred in Africa.
  • The present review focuses on the treatment of an AIDS-defining malignancy, Burkitt lymphoma, since the discovery of the tumor in 1958 to provide a backdrop to the increasing necessity of dealing with AIDS-associated Burkitt lymphoma in Africa.
  • RECENT FINDINGS: In Africa, it appears that AIDS-associated Burkitt lymphoma is increasing, but although treatment outcome is presently poor, the demonstration that highly active antiretroviral therapy permits the same treatment results to those in AIDS-unassociated Burkitt lymphoma provides hope for the future.
  • SUMMARY: In the 1960s, the extraordinary response of Burkitt lymphoma to chemotherapy provided considerable encouragement to pioneer oncologists.
  • Within little more than a decade, the most active drugs, the value of combination chemotherapy, and the need for intrathecal treatment, as well as the risk of tumor lysis syndrome had been demonstrated, providing a platform on which further advances could be made in resource-rich countries.
  • The impact of the HIV epidemic on the epidemiology and treatment of African Burkitt lymphoma will receive increasing focus in the coming years.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620863.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  •  go-up   go-down


12. Suzuki K, Nakazato T, Sanada Y, Mihara A, Tachikawa N, Kurai H, Yoshimura Y, Hayashi H, Yoshida S, Kakimoto T: [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma]. Rinsho Ketsueki; 2010 Mar;51(3):207-12
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma].
  • Colonoscopy was performed and histological examination of the colon tumor revealed Burkitt's lymphoma (BL).
  • In the HAART era, the survival of patients with AIDS-related diffuse large cell lymphoma (DLCL) improved dramatically, whereas the survival of similarly treated patients with AIDS-related BL remained poor.
  • Our case suggests that intensive chemotherapy with hyper-CVAD/MTX-Ara-C combined with HAART may be well tolerated and effective in AIDS-related BL.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Colonic Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379116.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CVAD protocol; EPOCH protocol
  •  go-up   go-down


13. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S155-60
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.
  • BACKGROUND: Strategies to circumvent or lessen the myelotoxicity associated with combination chemotherapy may improve the overall outcome of the management of patients particularly in resource poor settings.
  • OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.
  • CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.
  • Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.
  • This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619692.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine
  • [Number-of-references] 38
  •  go-up   go-down


14. Siani LM, Siani A, Ricci V, D'Elia M, Masoni T, Uggeri G: [Burkitt's lymphoma of the caecum in a patient with AIDS: clinical case and review of the literature]. Minerva Chir; 2009 Apr;64(2):229-33
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Burkitt's lymphoma of the caecum in a patient with AIDS: clinical case and review of the literature].
  • [Transliterated title] Linfoma di Burkitt del cieco in paziente con AIDS conclamato: caso clinico e revisione della letteratura.
  • The incidence of primary colic lymphoma, above all in the non-Hodgkin variant, is clearly higher in the HIV positive population, especially in subjects with AIDS.
  • The authors present the case of a 51-year-old patient with AIDS undergoing antiviral therapy; he was suffering from abdominal pain and presented a palpable mass in the right iliac fossa; diagnosis was caecal non-Hodgkin lymphoma (NHL); radical right hemicolectomy was carried out with definitive histological diagnosis of Burkitt-type small cell NHL.
  • Nevertheless such cases are comparatively frequent in patients with HIV virus, especially in the active phase and clinically proven to be due to immunodeficient syndrome.
  • Of cardinal importance is the differential diagnosis between primary and secondary forms because of the different treatment and prognosis.
  • Frequently such forms are observed in patients with AIDS, at advanced stages and with differentiated and hence more aggressive histotypes, also because they are present in organisms weakened by the underlying disease and by immunodeficiency.
  • Primary NHLs of the colon are relatively frequent and aggressive in patients with AIDS; early diagnosis and treatment are therefore of fundamental importance to improve the oncological outcome for these patients.
  • [MeSH-major] Burkitt Lymphoma. Cecal Neoplasms. Immunocompromised Host. Lymphoma, AIDS-Related
  • [MeSH-minor] Abdominal Pain / etiology. Diagnosis, Differential. HIV-1 / isolation & purification. Humans. Male. Middle Aged. Treatment Outcome


15. Freudenberg S, Palma P, Grobholz R, Ngendahayo L, Post S: HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case. Dis Colon Rectum; 2005 Aug;48(8):1656-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.
  • PURPOSE: This article describes and discusses primary Burkitt's lymphoma of the anus which is an extremely rare site of origin.
  • Histopathology and immunohistology provided evidence of an Epstein-Barr virus-associated Burkitt's lymphoma.
  • CONCLUSIONS: Because of the AIDS epidemic and the increase of anal malignant pathologies, anal Burkitt's lymphoma may appear more frequently.
  • Adequate treatment is available for only a small percentage of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adult. Colostomy. Fatal Outcome. HIV Seropositivity / diagnosis. Herpesvirus 4, Human / isolation & purification. Humans. Male. Rectum / surgery

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034658.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Levine AM: Management of AIDS-related lymphoma. Curr Opin Oncol; 2008 Sep;20(5):522-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of AIDS-related lymphoma.
  • PURPOSE OF REVIEW: With the advent of highly active antiretroviral therapy, the epidemiology of AIDS-lymphoma has changed, and prognosis has improved.
  • Although the incidence of AIDS-lymphoma has decreased, the incidence of HIV-associated Hodgkin's lymphoma has increased; mechanisms for these changes in epidemiology will be discussed.
  • The use of rituximab, while initially controversial because of reports of increased risk of infectious death, is associated with improved outcome; the increased risk of infectious death has not been confirmed.
  • The infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin regimen is associated with excellent results.
  • High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50-80% of patients with relapsed/refractory AIDS-lymphoma.
  • Addition of rituximab is associated with improved response rates, without an increase in infections.
  • Infusional etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin is associated with excellent results among patients with either diffuse large B cell lymphoma or Burkitt's lymphoma.
  • Optimal therapy for patients with HIV-Hodgkin's lymphoma has not yet been defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106654.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


17. Bolarinwa RA, Ndakotsu MA, Oyekunle AA, Salawu L, Akinola NO, Durosinmi MA: AIDS-related lymphomas in Nigeria. Braz J Infect Dis; 2009 Oct;13(5):359-61
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related lymphomas in Nigeria.
  • Aggressive non-Hodgkin's lymphoma (NHL), including primary central nervous system (CNS) lymphoma, lymphoblastic lymphoma and non-endemic Burkitt's lymphoma have been recognized as AIDS-defining cancers in most developed countries.
  • However, HIV/AIDS epidemics appear not to have been associated with higher incidence of lymphomas in Africa.
  • We therefore carried out this study to highlight the significance or otherwise of HIV/AIDS epidemics in the pathogenesis of lymphomas in a population of Nigerians with the disease.
  • Patients with a histological diagnosis of malignant chronic lymphoproliferative diseases {non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), Burkitt's lymphoma (BL) and Hodgkin lymphoma (HL)} at the Obafemi Awolowo University Teaching Hospitals' Complex, Ile-Ife from January 1993 to August 2008 were noted.
  • Those patients confirmed to be HIV/AIDS positive among the cohort with lymphomas were retrospectively studied using their clinical case notes.
  • A total of 391 patients were histologically confirmed to have lymphoma {NHL-109, (27.9%); CLL-76, (19.4%); BL-178, (45.5%) and HL-28, (7.2%)} during the study period.
  • The prevalence of AIDS-related lymphomas is 2.3% compared to 4.4% found in the general population.
  • However, it is interesting that no single case of AIDS-associated BL was seen, despite the fact that Burkitt's lymphoma is endemic in this part of the world.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428636.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


18. Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara C, Orkin C, Nelson M, Johnson M, Bower M, Cwynarski K: Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS; 2010 Mar 27;24(6):851-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
  • OBJECTIVE AND DESIGN: : To retrospectively describe the recovery of cellular immunity and the clinical outcome of 30 patients with HIV-associated Burkitt's lymphoma (HIV-BL), who were treated with the intensive chemotherapy CODOX-M/IVAC and HAART as part of their standard care.
  • The median CD4 cell count at diagnosis of HIV-BL was 171/ml (range: 4-848) and the plasma HIV viral load was undetectable in five of 29 patients.
  • Viral load was undetectable in 88% and CD4 cell count more than 200/ml in 58% of patients assessed 6 months after completing chemotherapy, and in 87 and 80% at 12 months, respectively.
  • CONCLUSION: : The intensive regimen CODOX-M/IVAC, a feasible and effective chemotherapy, is associated with an excellent immunological recovery in patients with HIV-BL on HAART.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy


19. Gujral S, Shet TM, Kane SV: Morphological spectrum of AIDS-related plasmablastic lymphomas. Indian J Pathol Microbiol; 2008 Jan-Mar;51(1):121-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological spectrum of AIDS-related plasmablastic lymphomas.
  • We have had a recent spurt in cases of AIDS-related lymphoma (ARL) at our centre.
  • Most of these cases are aggressive mature B cell lymphomas, mainly plasmablastic lymphoma (PBL) and diffuse large B-cell lymphoma (DLBCL).
  • Diagnosis was based on morphology, immunohistochemistry, proliferation index, HIV positive status and its preference to extranodal sites (mostly mucosa based).
  • We classified PBL into three morphological subtypes (immunoblastic - 25, Burkitt's - 7, plasmacytic - 2).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunoglobulin Light Chains / analysis. Leukemia, Plasma Cell / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Male. Middle Aged. Syndecan-1 / analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417882.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Immunoglobulin Light Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


20. Hishima T, Oyaizu N, Fujii T, Tachikawa N, Ajisawa A, Negishi M, Nakamura T, Iwamoto A, Hayashi Y, Matsubara D, Sasao Y, Kimura S, Kikuchi Y, Teruya K, Yasuoka A, Oka S, Saito K, Mori S, Funata N, Sata T, Katano H: Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy. Microbes Infect; 2006 Apr;8(5):1301-7
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decrease in Epstein-Barr virus-positive AIDS-related lymphoma in the era of highly active antiretroviral therapy.
  • Recent introduction of highly active antiretroviral therapy (HAART) is reported to have reduced the incidence of lymphoma among HIV-infected individuals.
  • A clinicopathological study was performed on 86 AIDS-related lymphoma patients who were treated in Tokyo area from 1987 to 2005.
  • The incidence of lymphoma detected by autopsy was 27% (53 cases/198 autopsies).
  • Diffuse large B cell lymphoma was the most predominant histological subtype throughout the period (78%).
  • Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users.
  • Epstein-Barr virus (EBV)-positive lymphoma decreased from 88% in the pre-HAART era to 58% in the HAART era, but did not differ significantly between HAART users (73%) and non-users (74%).
  • Nodal involvement of lymphoma increased from 14% in the pre-HAART era to 50% in the HAART era; however, central nervous system involvement decreased from 62 to 38%.
  • Kaposi's sarcoma-associated herpesvirus infection was rare (4%) among all cases.
  • These data suggest that HAART might play a partial role in these changes, and the alteration in immunological backgrounds, such as EBV prevalence, is suggested as another leading cause of these changes in Japanese AIDS-related lymphoma.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697236.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


21. Epeldegui M, Breen EC, Hung YP, Boscardin WJ, Detels R, Martínez-Maza O: Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis. AIDS; 2007 Nov 12;21(17):2265-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis.
  • Non-Hodgkin's B cell lymphoma (NHL) is a common cancer in HIV infection.
  • Since NHL is a common cancer in HIV infection, and expression of AID could contribute to the development of NHL, we hypothesized that AID expression would be elevated in those who went on to develop AIDS-associated NHL (AIDS-NHL).
  • AID mRNA levels were measured by TaqMan RT-PCR in peripheral blood mononuclear cells, obtained prior to AIDS-NHL diagnosis, from 16 HIV-infected subjects who developed AIDS-NHL, and from control subjects (AIDS but no NHL, and HIV-negative subjects).
  • PBMC AID expression was markedly elevated in those who developed AIDS-NHL, when compared to AIDS and HIV-negative controls.
  • Additionally, AID expression was seen to differ depending on NHL subtype, with the highest levels of expression seen in those who developed Burkitt's lymphoma.
  • [MeSH-major] B-Lymphocytes / enzymology. Cytidine Deaminase / genetics. Gene Expression Regulation, Viral. Lymphoma, AIDS-Related / enzymology. Lymphoma, B-Cell / enzymology
  • [MeSH-minor] Adult. California. Case-Control Studies. Cell Transformation, Viral. Cohort Studies. Enzyme Induction. Humans. Lymphocyte Activation. Male. RNA, Viral / blood. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18090274.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH HHS / CA / CA57152; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


22. Hassan A, Kreisel F, Gardner L, Lewis JS Jr, El-Mofty SK: Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status. Head Neck Pathol; 2007 Dec;1(2):150-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of head and neck: report of two new cases and correlation with c-myc and IgVH gene mutation status.
  • Plasmablastic lymphoma (PBL) is a rare acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma (AIDS-NHL), with predilection for the mucosa of oral cavity.
  • It usually has a plasmablastic morphology, expressing plasma cell-associated antigens with weak or absent expression of B-cell-associated markers.
  • For the first time we report a case of AIDS-related PBL that, by fluorescence in situ hybridization (FISH), shows a c-myc gene rearrangement.
  • Although current literature suggests that most cases of c-myc gene rearranged AIDS-NHL are Burkitt's lymphoma, our case has an immunophenotype characteristic for PBL.
  • The concurrent B-cell immunophenotype of BCL-6(-)/CD138(+)/MUM-1(+) also suggests a post-germinal center B-cell origin of this lymphoma.
  • The immunophenotype of our second case (BCL-6(-)/CD138(+)/MUM-1(+)) also suggests a post-germinal center B-cell origin.
  • [MeSH-major] Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Mouth Neoplasms / pathology. Proto-Oncogene Proteins c-myc / genetics

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):77-81 [15621784.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Cancer. 2005 Jun 25;105(3):139-44 [15803491.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Aug;100(2):198-206 [16037778.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • [Cites] Hum Pathol. 2002 Apr;33(4):392-404 [12055673.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3928-32 [14581416.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):95-100 [9709310.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1993 Jan 1;81(1):166-76 [8380252.001]
  • [Cites] Blood. 1993 Jul 15;82(2):552-63 [8392399.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):67-82 [9044511.001]
  • (PMID = 20614267.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ PMC2807524
  • [Keywords] NOTNLM ; Acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma / Immunoglobulin variable heavy chain hypermutation status / Plasmablastic lymphoma / c-myc gene rearrangement
  •  go-up   go-down


23. Chao C, Xu L, Abrams D, Leyden W, Horberg M, Towner W, Klein D, Tang B, Silverberg M: Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy. AIDS; 2010 Jul 17;24(11):1765-70
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy.
  • OBJECTIVE: To investigate the survival outcomes for non-Hodgkin lymphoma (NHL) in HIV-infected vs. uninfected patients from the same integrated healthcare system, and to identify prognostic factors for HIV-related NHL in the era of combined antiretroviral therapy.
  • Two-year all-cause and lymphoma-specific mortality by HIV status were examined using multivariable Poisson regression.
  • Among HIV-infected patients, prognostic factors of demographics, lymphoma, and HIV-related characteristics for the same outcomes were also examined.
  • Fifty-nine percent of HIV-infected patients died within 2 years after NHL diagnosis as compared with 30% of HIV-uninfected patients.
  • HIV status was independently associated with a doubling of 2-year all-cause mortality (relative risk = 2.0, 95% confidence interval 1.7-2.3).
  • This elevated mortality risk for HIV-infected patients was similar for all race groups, lymphoma stages, and histologic subtypes.
  • HIV-infected patients with CD4 cell count below 200 cells/microl, prior AIDS-defining illness, or both were also at increased risk for lymphoma-specific mortality as compared with HIV-uninfected patients.
  • Among HIV-infected NHL patients, significant prognostic factors for overall mortality included prior AIDS-defining illness and Burkitt's subtype.
  • Better management and therapeutic approaches to extend survival time for HIV-related NHL are needed.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • [Cites] AIDS Read. 2004 Nov;14(11):605-17 [15570672.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] Leuk Lymphoma. 2001 Mar;41(1-2):105-16 [11342362.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):237-42 [11860669.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Aug 15;30(5):478-84 [12154338.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Clin Infect Dis. 2003 Dec 1;37(11):1556-64 [14614680.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):142-4 [14679461.001]
  • [Cites] Am J Epidemiol. 2004 Aug 15;160(4):301-5 [15286014.001]
  • [Cites] HIV Med. 2004 Sep;5(5):377-84 [15369514.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2943-6 [15238428.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8477-82 [16230675.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]
  • [Cites] Antivir Ther. 2007;12(6):931-9 [17926647.001]
  • [Cites] Lancet. 2009 Apr 18;373(9672):1352-63 [19361855.001]
  • [Cites] AIDS. 2009 Nov 13;23(17):2337-45 [19741479.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):155-63 [11148572.001]
  • (PMID = 20453630.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA134234-01; United States / NIAID NIH HHS / AI / AI071725-01A1; United States / NIAID NIH HHS / AI / K01 AI071725; United States / NCI NIH HHS / CA / R01 CA134234-01; United States / NIAID NIH HHS / AI / K01 AI071725-01A1; United States / NCI NIH HHS / CA / R01CA134234; United States / NIAID NIH HHS / AI / K01AI071725; United States / NCI NIH HHS / CA / R01 CA134234
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Other-IDs] NLM/ NIHMS198983; NLM/ PMC2895006
  •  go-up   go-down


24. Dinh MH, Matkowskyj KA, Stosor V: Colorectal lymphoma in the setting of HIV: case report and review of the literature. AIDS Patient Care STDS; 2009 Apr;23(4):227-30
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal lymphoma in the setting of HIV: case report and review of the literature.
  • The incidence of Burkitt's lymphoma, a rare and aggressive form of non-Hodgkin's lymphoma, remains unaffected by immune reconstitution in HIV-infected individuals.
  • A flexible sigmoidoscopy with biopsy of the rectum and peripheral blood smear with bone marrow examination revealed immunophenotypic and cytogenic findings diagnostic of Burkitt's lymphoma of the rectum.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Colorectal Neoplasms / diagnosis. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis


25. Lubega J: T-helper 1 versus T-helper 2 lymphocyte immunodysregulation is the central factor in genesis of Burkitt lymphoma: hypothesis. Infect Agent Cancer; 2007;2:10
HIV InSite. treatment guidelines - Malaria and HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-helper 1 versus T-helper 2 lymphocyte immunodysregulation is the central factor in genesis of Burkitt lymphoma: hypothesis.
  • BACKGROUND: The HIV epidemic has challenged our previous understanding of endemic Burkitt's lymphoma.
  • Despite the strong association of Burkitt's lymphoma and HIV infection in the Developed world, and against previous postulations that the cancer is due to immunosupression among African children, the HIV epidemic in the Malaria belt has not been associated with a corresponding increase in incidence of childhood Burkitt's lymphoma.
  • Even outside the context of HIV infection, there is substantial evidence for a strong but skewed immune response towards a TH2 response in genesis of Burkitt lymphoma.
  • PRESENTATION OF THE HYPOTHESIS: Rather than a global and/or profound immunosupression, the final common pathway in genesis of Burkitt's lymphoma is the dysregulation of the immune response towards a TH2 response dominated by B-lymphocytes, and the concomitant suppression of the TH1 cell-mediated immune surveillance, driven by various viral/parasitic/bacterial infections.
  • TESTING THE HYPOTHESIS: Case control studies comparing TH2 and TH1 immune responses in Burkitt lymphoma of different etiological types (sporadic, HIV-related, endemic and post-transplant) to demonstrate significant dominance of TH2 immune response in presence of poor CMI response as a common factor.
  • Immunological profiling to evaluate differences between immune states that are associated (such as recurrent Malaria infection) and those that are not associated (such as severe protein-energy malnutrition) with Burkitt lymphoma.
  • Prospective cohorts profiling chronology of immunological events leading to Burkitt lymphoma in children with EBV infection.
  • IMPLICATIONS OF THE HYPOTHESIS: The dysregulation of the immune response may be the missing link in our understanding of Burkitt lymphomagenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Sci Publ. 1985;(60):177-86 [3905588.001]
  • [Cites] P N G Med J. 1986 Mar;29(1):41-3 [3019040.001]
  • [Cites] Proc R Soc Med. 1971 Sep;64(9):909-10 [4329792.001]
  • [Cites] Clin Exp Immunol. 1984 May;56(2):371-6 [6329564.001]
  • [Cites] Prog Food Nutr Sci. 1984;8(3-4):193-228 [6396715.001]
  • [Cites] Fed Proc. 1980 Nov;39(13):3098-104 [6968692.001]
  • [Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]
  • [Cites] Arch Dis Child. 1995 Aug;73(2):100-4; discussion 104-5 [7574850.001]
  • [Cites] Immunol Rev. 1994 Aug;140:73-92 [7821929.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] AIDS. 1996 Jun;10(6):643-7 [8780819.001]
  • [Cites] Am J Pathol. 1976 Sep;84(3):599-614 [8988.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):987-94 [9402172.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Cent Afr J Med. 1998 Oct;44(10):242-5 [10101432.001]
  • [Cites] N Engl J Med. 2000 Aug 17;343(7):481-92 [10944566.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] J Gen Virol. 2001 Dec;82(Pt 12):3051-5 [11714983.001]
  • [Cites] J Natl Cancer Inst. 1976 Mar;56(3):479-83 [1255780.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]
  • [Cites] Ann Med Interne (Paris). 2003 Dec;154(8):523-8 [15037828.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Int J Immunopharmacol. 1992 Apr;14(3):361-6 [1618590.001]
  • [Cites] Mol Immunol. 2007 Feb;44(5):934-42 [16730063.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]
  • [Cites] Transplantation. 2006 Oct 27;82(8):1013-23 [17060848.001]
  • [Cites] Eur J Cancer Prev. 2007 Feb;16(1):55-61 [17220705.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2466-72 [1933784.001]
  • [Cites] Int J Cancer. 1990 Apr 15;45(4):650-3 [2323841.001]
  • [Cites] Paediatr Perinat Epidemiol. 1990 Jul;4(3):303-24 [2374749.001]
  • [Cites] Am J Epidemiol. 1989 Apr;129(4):740-52 [2923122.001]
  • [Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]
  • (PMID = 17509139.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1884132
  •  go-up   go-down


26. Nogueira MV, Vidal L, Terra B, Pagot T, Salluh JI, Soares M: Hemophagocytic syndrome associated with cytomegalovirus infection in a severely immunocompromised AIDS patient: case report. Braz J Infect Dis; 2009 Feb;13(1):72-3
MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemophagocytic syndrome associated with cytomegalovirus infection in a severely immunocompromised AIDS patient: case report.
  • Hemophagocytic syndrome is a clinical condition characterized by the infiltration of the bone marrow and reticuloendothelial system by macrophages and activated histiocytes, leading to uncontrolled phagocytosis of platelets, erythrocytes, lymphocytes and precursor cells.
  • This syndrome is classified as familial or acquired; the latter is more frequent and is associated with diverse conditions, such as infections, malignancies and rheumatic diseases.
  • We report a case of HLH associated with cytomegalovirus infection in a patient with acquired-immunodeficiency syndrome and Burkitt's lymphoma.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Cytomegalovirus Infections / diagnosis. Immunocompromised Host. Lymphohistiocytosis, Hemophagocytic / diagnosis
  • [MeSH-minor] Adult. Burkitt Lymphoma / complications. Humans. Male. Severity of Illness Index

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578635.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


27. Butt FM, Chindia ML, Rana F, Machigo FG: Pattern of head and neck malignant neoplasms in HIV-infected patients in Kenya. Int J Oral Maxillofac Surg; 2008 Oct;37(10):907-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most commonly reported neoplasms of the head and neck region include Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL).
  • There is also an increased risk of oral squamous cell carcinoma (SCC).
  • A descriptive cross-sectional study including HIV-infected patients with neoplastic and non-neoplastic lesions was conducted.
  • The prevalence of neoplastic lesions in this study was 27%; 37 (68%) patients had KS, 9 (17%) had SCC, 7 (13%) had NHL and 1 (2%) had Burkitt's lymphoma.
  • In this study, the most common malignant neoplasms were KS, SCC and NHL, manifesting in a younger age group than in the non-HIV group of patients.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Burkitt Lymphoma / epidemiology. Candidiasis, Oral / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cheilitis / epidemiology. Cross-Sectional Studies. Female. Humans. Kenya / epidemiology. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Mouth Neoplasms / epidemiology. Prevalence. Sarcoma, Kaposi / epidemiology. Sex Factors. Stomatitis, Aphthous / epidemiology. Young Adult


28. Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV: Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? Eur J Haematol; 2007 Feb;78(2):152-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first case is that of a lymph node sample from a 40-yr-old non-Hodgkin's lymphoma (NHL) patient sent for determination of disease progress.
  • Cytogenetic studies of lymph node showed multiple clonal abnormalities, most notably a der(18) from a t(14;18) which is associated with high-grade NHL.
  • After two cycles of chemotherapy with fludarabine, the patient did not show any clinical response, suggesting possible progression to high-grade lymphoma.
  • The second case is of a patient with a history of human immunodeficiency virus and blastic natural killer leukemia/lymphoma.
  • Hematologic studies of ascitic fluid classified the patient as having pleural effusion lymphoma whereas bone marrow analysis showed no malignancy.
  • Bone marrow cytogenetic studies showed multiple clonal abnormalities including a t(8;14), which is commonly associated with Burkitt's lymphoma (BL).
  • To our knowledge, this is the first case wherein a morphologically normal bone marrow showed presence of clonal abnormalities consistent with BL or Pleural effusion lymphoma.
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Follicular / genetics. Lymphoma, Non-Hodgkin / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313561.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


29. Mendiolaza J, Baltasar JF, Anis A, Harrison J, Chen F, Klapholz M, Saric M: Left ventricular non-Hodgkin lymphoma visualized on contrast echocardiography. J Clin Ultrasound; 2007 Oct;35(8):462-4
Hazardous Substances Data Bank. Octafluoropropane .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ventricular non-Hodgkin lymphoma visualized on contrast echocardiography.
  • We present a case of AIDS-related Burkitt's type cardiac lymphoma in a middle-aged woman with Epstein-Barr virus infection and profound immunodeficiency.
  • The original features of our case include left ventricular location, female sex, and the use of contrast echocardiography to help establish the diagnosis.
  • [MeSH-major] Contrast Media / administration & dosage. Fluorocarbons. Heart Neoplasms / ultrasonography. Lymphoma, Non-Hodgkin / ultrasonography
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Heart Ventricles / ultrasonography. Humans. Injections, Intravenous. Microspheres

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • (PMID = 17373683.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Fluorocarbons; CK0N3WH0SR / perflutren
  •  go-up   go-down


30. Lan K, Verma SC, Murakami M, Bajaj B, Robertson ES: Epstein-Barr Virus (EBV): infection, propagation, quantitation, and storage. Curr Protoc Microbiol; 2007 Aug;Chapter 14:Unit 14E.2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) was first reported as the etiological agent of Burkitt's lymphoma in 1964.
  • Since then, EBV has also been associated with nasopharyngeal carcinoma, which is highly prevalent in Southeast Asia, as well as infectious mononucleosis, complications of AIDS, and transplant-related B cell lymphomas.
  • This virus has further been linked with T cell lymphomas and Hodgkin's disease, establishing the concept of a wide spectrum of EBV-associated malignant disorders.
  • So far, there are a number of EBV-infected cell lines established that can be induced for production of infectious viral progeny and that facilitate the study of the mechanism of EBV-related infection, transformation, and oncogenesis.
  • [MeSH-major] B-Lymphocytes / virology. Cell Transformation, Viral. Epithelial Cells / virology. Herpesvirus 4, Human. Virology / methods
  • [MeSH-minor] Animals. Cell Line. Cells, Cultured. Culture Media. Humans. Mice. Specimen Handling / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18770612.001).
  • [ISSN] 1934-8533
  • [Journal-full-title] Current protocols in microbiology
  • [ISO-abbreviation] Curr Protoc Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media
  •  go-up   go-down


31. Mwakigonja AR, Kaaya EE, Mgaya EM: Malignant lymphomas (ML) and HIV infection in Tanzania. J Exp Clin Cancer Res; 2008;27:9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.
  • The ML frequency, pathogenicity, clinical patterns and possible association with AIDS in Tanzania, are not well documented impeding the development of preventive and therapeutic strategies.
  • METHODS: Sections of 176 archival formalin-fixed paraffin-embedded biopsies of ML patients at Muhimbili National Hospital (MNH)/Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania from 1996-2001 were stained for hematoxylin and eosin and selected (70) cases for expression of pan-leucocytic (CD45), B-cell (CD20), T-cell (CD3), Hodgkin/RS cell (CD30), histiocyte (CD68) and proliferation (Ki-67) antigen markers.
  • RESULTS: The proportion of ML out of all diagnosed tumors at MNH during the 6 year period was 4.2% (176/4200) comprising 77.84% non-Hodgkin (NHL) including 19.32% Burkitt's (BL) and 22.16% Hodgkin's disease (HD).
  • Supra-diaphragmatic presentation was commonest and histological sub-types were mostly aggressive B-cell lymphomas however, no clear cases of primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) were diagnosed.
  • CONCLUSION: Malignant lymphomas apparently, increased significantly among diagnosed tumors at MNH between 1996 and 2001, predominantly among the young, HIV infected and AIDS patients.
  • The frequent aggressive clinical and histological presentation as well as the dominant B-immunophenotype and the HIV serology indicate a pathogenic association with AIDS.
  • Therefore, routine HIV screening of all malignant lymphoma patients at MNH is necessary to enable comprehensive ARL diagnosis and formulation of preventive and therapeutic protocols.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology. Burkitt Lymphoma / virology. Child. Child, Preschool. Female. HIV Seropositivity. Hodgkin Disease / epidemiology. Hodgkin Disease / etiology. Hodgkin Disease / virology. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Lymphoma, Non-Hodgkin / virology. Male. Middle Aged. Tanzania / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Clin (Barc). 2000 Jan 15;114(1):19-21 [10782456.001]
  • [Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]
  • [Cites] Med Trop (Mars). 1999;59(4 Pt 2):499-502 [10901854.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1301-9 [10914556.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):383-94 [10975544.001]
  • [Cites] Med Oncol. 2001;18(1):15-22 [11778965.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):383-90 [11897040.001]
  • [Cites] East Afr Med J. 2000 Aug;77(8):435-9 [12862069.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] East Afr Med J. 1966 Jul;43(7):274-83 [5911333.001]
  • [Cites] Br Med Bull. 1971 Jan;27(1):14-20 [5100946.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):186-9 [6893012.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Nov;89(6):417-24 [6278823.001]
  • [Cites] East Afr Med J. 1982 Apr;59(4):256-60 [7140611.001]
  • [Cites] Ann Trop Paediatr. 1984 Jun;4(2):83-5 [6083750.001]
  • [Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1865-73 [2004300.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] Curr Opin Oncol. 1994 Sep;6(5):489-91 [7827151.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):48-53 [9044509.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Blood. 1999 Feb 15;93(4):1364-71 [9949180.001]
  • [Cites] Bull Cancer. 1999 Jun;86(6):529-36 [10417426.001]
  • [Cites] J Pak Med Assoc. 1999 Jan;49(1):11-5 [10463009.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S63-7 [15622604.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S90-6 [15622607.001]
  • [Cites] East Afr Med J. 2004 Aug;81(8):384-7 [15622930.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]
  • [Cites] Curr HIV/AIDS Rep. 2005 Aug;2(3):146-53 [16091262.001]
  • [Cites] Indian Pediatr. 2006 Feb;43(2):141-7 [16528110.001]
  • [Cites] Herpes. 2006 May;13(1):12-6 [16732997.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1291-9 [17487381.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1806-12 [17557295.001]
  • [Cites] Cancer Sci. 2008 Feb;99(2):345-9 [18201268.001]
  • [Cites] Malays J Pathol. 1999 Jun;21(1):45-50 [10879278.001]
  • (PMID = 18577266.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2438337
  •  go-up   go-down


32. Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES: Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther; 2009 Nov;8(22):2136-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a common cancer in AIDS patients closely associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • Previously, we showed that KSHV latency associated nuclear antigen (LANA) stabilizes intracellular activated Notch1 (ICN) involved in maintenance of the malignant phenotype of KSHV infected PEL cells in vitro.
  • The gamma-secretase inhibitor (GSI) which specifically blocks the production of ICN slows down the proliferation of the KSHV infected PEL cell lines BCBL1, BC3 as well as JSC1 in vitro.
  • We observed that the onset of tumorigenesis of KSHV infected PELs was significantly delayed in GSI treated SCID mice harboring the PEL cell lines.
  • We also found that GSI treatment resulted in necrosis as well as apoptosis in tumors generated by the xenotransplanted KSHV positive PEL cell lines.
  • In contrast, GSI had no effect on mice harboring BJAB cells, a KSHV negative Burkitt's lymphoma cell line where ICN levels were negligible.
  • Our study provides further evidence to suggest that targeted downregulation of abnormal Notch signaling has therapeutic potential for KSHV related primary effusion lymphomas.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Dipeptides / therapeutic use. Herpesviridae Infections. Herpesvirus 8, Human / pathogenicity. Lymphoma, Primary Effusion / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, Notch1 / antagonists & inhibitors. Tumor Virus Infections
  • [MeSH-minor] Animals. Antigens, Viral / physiology. Apoptosis. Burkitt Lymphoma / pathology. Cell Line, Tumor / transplantation. Herpesvirus 4, Human / isolation & purification. Herpesvirus 4, Human / pathogenicity. Mice. Mice, Inbred NOD. Mice, SCID. Necrosis. Nuclear Proteins / physiology. Random Allocation. Signal Transduction / drug effects. Specific Pathogen-Free Organisms. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(22):2144-6 [20068386.001]
  • (PMID = 19783901.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / PHS HHS / / A1067037; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / CA108461; United States / NIDCR NIH HHS / DE / DE017338
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Dipeptides; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Neoplasm Proteins; 0 / Notch1 protein, mouse; 0 / Nuclear Proteins; 0 / Receptor, Notch1; 0 / latency-associated nuclear antigen; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


33. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, Ramos JC, Luz E, Pedroso C, Manrique M, Toomey NL, Brites C, Dittmer DP, Harrington WJ Jr: EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res; 2008 Mar 1;68(5):1436-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression pattern of these miRNAs in clinical samples of EBV-associated non-Hodgkin's lymphomas is unknown.
  • We analyzed five primary "endemic" pediatric Burkitt's lymphomas (BL), two acquired immunodeficiency syndrome (AIDS)-related type I latency BL lines, a type III latency line, three EBV(+) primary effusion lymphomas (PEL), and three AIDS-related diffuse large B-cell lymphomas (DLBCL) for expression of EBV-encoded miRNAs.
  • BHRF1-3 miRNA expression inversely correlated with levels of a putative cellular target, the IFN-inducible T-cell attracting chemokine CXCL-11/I-TAC, and suppression of this factor was reversed by transfection of an antisense oligo to the EBV miRNA BHRF1-3.
  • EBV-encoded miRNAs are expressed in primary lymphomas classically linked to the virus and are associated with the viral latency status.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Microbiol. 2000;54:19-48 [11018123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16164-9 [17911266.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1098-104 [12219084.001]
  • [Cites] J Gen Virol. 2003 Apr;84(Pt 4):949-57 [12655096.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Virology. 2004 May 20;323(1):141-52 [15165826.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30219-27 [15150261.001]
  • [Cites] RNA. 2004 Aug;10(8):1165-73 [15272116.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8058-62 [1325642.001]
  • [Cites] J Virol. 1993 Jun;67(6):3182-90 [8388496.001]
  • [Cites] J Virol. 1995 Feb;69(2):1132-41 [7815492.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1493-501 [7632957.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Hum Pathol. 1997 Dec;28(12):1408-14 [9416698.001]
  • [Cites] Science. 1998 Apr 10;280(5361):248-53 [9535648.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):2009-21 [9625760.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1290-7 [15741182.001]
  • [Cites] Science. 2005 Apr 22;308(5721):557-60 [15845854.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):682-6 [15931223.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] J Immunother. 2005 Jul-Aug;28(4):343-51 [16000952.001]
  • [Cites] Science. 2005 Sep 2;309(5740):1519-24 [16141061.001]
  • [Cites] Development. 2005 Nov;132(21):4645-52 [16224044.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):e182 [16314296.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Mamm Genome. 2006 Mar;17(3):189-202 [16518686.001]
  • [Cites] Curr Opin Genet Dev. 2006 Apr;16(2):203-8 [16503132.001]
  • [Cites] Vaccine. 2006 Apr 5;24(15):2966-74 [16503368.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] PLoS Pathog. 2007 May 11;3(5):e65 [17500590.001]
  • [Cites] J Virol. 2007 Sep;81(18):9967-75 [17626073.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):635-43 [12115495.001]
  • (PMID = 18316607.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA082274; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA70058; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA121935; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935; United States / NIDCR NIH HHS / DE / DE018304-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BHRF1 protein, Human herpesvirus 4; 0 / CXCL11 protein, human; 0 / Chemokine CXCL11; 0 / MicroRNAs; 0 / Oligonucleotides, Antisense; 0 / Viral Proteins; EC 3.1.- / Ribonucleases
  • [Other-IDs] NLM/ NIHMS191351; NLM/ PMC2855641
  •  go-up   go-down


34. Spina M, Gloghini A, Tirelli U, Carbone A: Therapeutic options for HIV-associated lymphomas. Expert Opin Pharmacother; 2010 Oct;11(15):2471-81
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic options for HIV-associated lymphomas.
  • IMPORTANCE OF THE FIELD: The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population.
  • AREAS COVERED IN THIS REVIEW: This review summarizes reports from 1995 to the present which focus on the treatment strategies and their prognostic relevance in the setting of HIV-associated lymphomas.
  • WHAT THE READER WILL GAIN: The identification of prognostic factors in rare tumors such as HIV-associated lymphomas is going to require the establishment of multi-institutional and cooperative group-supported tissue banks.
  • TAKE HOME MESSAGE: HIV-associated lymphomas still represent a relevant field of clinical research.
  • However, rituximab plus chemotherapy should be offered to the majority of patients with HIV infection and diffuse large B-cell lymphomas; and the feasibility of intensive aggressive chemotherapy regimens has been successfully tested in HIV-associated Burkitt's lymphomas.
  • [MeSH-major] HIV Infections / complications. HIV Infections / drug therapy. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / trends. Boronic Acids / therapeutic use. Bortezomib. Epstein-Barr Virus Infections / complications. Epstein-Barr Virus Infections / drug therapy. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy. Pyrazines / therapeutic use. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726820.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Pyrazines; 0 / ofatumumab; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib
  •  go-up   go-down


35. Takacs M, Segesdi J, Banati F, Koroknai A, Wolf H, Niller HH, Minarovits J: The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas. Mediterr J Hematol Infect Dis; 2009;1(2):e2009012
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas.
  • Epstein-Barr virus (EBV), a human gammaherpesvirus, is associated with a series of malignant tumors.
  • These include lymphomas (Burkitt's lymphoma, Hodgkin's disease, T/NK-cell lymphoma, post-transplant lymphoproliferative disease, AIDS-associated lymphoma, X-linked lymphoproliferative syndrome), carcinomas (nasopharyngeal carcinoma, gastric carcinoma, carcinomas of major salivary glands, thymic carcinoma, mammary carcinoma) and a sarcoma (leiomyosarcoma).
  • The latent EBV genomes persist in the tumor cells as circular episomes, co-replicating with the cellular DNA once per cell cycle.
  • The expression of latent EBV genes is cell type specific due to the strict epigenetic control of their promoters.
  • Based on the cell type specific epigenetic marks associated with latent EBV genomes one can distinguish between viral epigenotypes that differ in transcriptional activity in spite of having an identical (or nearly identical) DNA sequence.
  • Whereas latent EBV genomes are regularly targeted by epigenetic control mechanisms in different cell types, EBV encoded proteins may, in turn, affect the activity of a set of cellular promoters by interacting with the very same epigenetic regulatory machinery.
  • EBNA3C (EBNA6) seems to be associated both with histone acetylases and deacetylases, although in separate complexes.
  • In epithelial cells LMP1 can up-regulate DNA methyltransferases and, in Hodgkin lymphoma cells, induce the Polycomb group protein Bmi-1.
  • These interactions may result in epigenetic dysregulation and subsequent cellular dysfunctions that may manifest in or contribute to the development of pathological changes (e.g. initiation and progression of malignant neoplasms, autoimmune phenomena, immunodeficiency).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1992 May 11;20(9):2287-91 [1594447.001]
  • [Cites] J Gen Virol. 1992 Jul;73 ( Pt 7):1687-92 [1321209.001]
  • [Cites] Virology. 1994 May 1;200(2):661-7 [8178450.001]
  • [Cites] J Virol. 1994 Sep;68(9):5375-83 [8057421.001]
  • [Cites] Science. 1995 Apr 28;268(5210):560-3 [7725102.001]
  • [Cites] Mol Cell Biol. 1995 Nov;15(11):6150-9 [7565767.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3129-36 [8874213.001]
  • [Cites] J Virol. 1997 Mar;71(3):1938-45 [9032325.001]
  • [Cites] Nat Genet. 1998 Jun;19(2):187-91 [9620779.001]
  • [Cites] J Mol Biol. 2005 Jul 22;350(4):631-40 [15967459.001]
  • [Cites] Am J Hematol. 2006 Jan;81(1):5-11 [16369970.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2493-500 [16304050.001]
  • [Cites] Cell. 2006 Apr 21;125(2):315-26 [16630819.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7065-70 [16606841.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):2995-3002 [16707594.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 [16966603.001]
  • [Cites] J Bacteriol. 2006 Dec;188(23):8160-8 [16997949.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5722-35 [10891508.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Virol. 2001 Mar;75(6):2584-96 [11222681.001]
  • [Cites] Semin Cancer Biol. 2001 Dec;11(6):469-76 [11669609.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):237-42 [17211412.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):457-66 [17334365.001]
  • [Cites] Nat Genet. 2007 Apr;39(4):442-3 [17392803.001]
  • [Cites] J Virol. 2007 Jun;81(12):6389-401 [17409162.001]
  • [Cites] EMBO J. 2007 Oct 3;26(19):4252-62 [17853891.001]
  • [Cites] J Virol. 2007 Dec;81(23):13242-7 [17898065.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):705-9 [18258198.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):787-94 [11891177.001]
  • [Cites] J Virol. 2002 May;76(10):4699-708 [11967287.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10084-9 [12110730.001]
  • [Cites] Blood. 2003 Jan 15;101(2):681-9 [12393683.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):4035-40 [12427740.001]
  • [Cites] J Virol. 2003 Apr;77(7):4261-72 [12634383.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1443-50 [12771413.001]
  • [Cites] J Virol. 2003 Jul;77(14):8166-72 [12829856.001]
  • [Cites] Virus Genes. 2003 Aug;27(1):57-66 [12913358.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11668-76 [17178861.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19278-83 [17159145.001]
  • [Cites] J Gen Virol. 2008 Jun;89(Pt 6):1364-70 [18474551.001]
  • [Cites] J Cell Physiol. 2008 Aug;216(2):321-6 [18484093.001]
  • [Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]
  • [Cites] J Virol. 2009 Apr;83(7):2930-40 [19129441.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2488-97 [19075189.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):158-64 [19429479.001]
  • [Cites] J Virol. 2009 Jul;83(14):7109-16 [19403674.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):430-5 [10618435.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2343-9 [10713158.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):131-7 [11801549.001]
  • [Cites] Adv Cancer Res. 2003;89:133-56 [14587872.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):475-8 [14617009.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1326-31 [14961078.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Trends Microbiol. 2004 Nov;12(11):495-9 [15488390.001]
  • [Cites] J Virol. 2004 Nov;78(22):12308-19 [15507618.001]
  • [Cites] Science. 1980 Nov 7;210(4470):604-10 [6254144.001]
  • [Cites] J Virol. 1983 May;46(2):446-53 [6302313.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806-10 [6328526.001]
  • [Cites] J Virol. 1998 Sep;72(9):7075-83 [9696800.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):46-56 [9858530.001]
  • [Cites] Science. 1999 May 7;284(5416):967-70 [10320378.001]
  • [Cites] Gene. 1999 Aug 5;236(1):87-95 [10433969.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] J Virol. 2004 Dec;78(24):14062-5 [15564516.001]
  • [Cites] Genes Dev. 2005 Mar 1;19(5):542-52 [15706033.001]
  • [Cites] Biochem Cell Biol. 2005 Jun;83(3):286-95 [15959556.001]
  • [Cites] Biochem Cell Biol. 2005 Jun;83(3):344-53 [15959560.001]
  • [Cites] J Gen Virol. 1985 Sep;66 ( Pt 9):1931-40 [2993484.001]
  • [Cites] Nature. 1986 May 15-21;321(6067):209-13 [2423876.001]
  • [Cites] Cell. 1986 Dec 26;47(6):883-9 [3022942.001]
  • [Cites] Adv Cancer Res. 1988;50:95-158 [2837072.001]
  • [Cites] Cell. 1988 Jul 1;54(1):127-35 [2838178.001]
  • [Cites] Cell. 1988 Nov 4;55(3):427-33 [2846181.001]
  • [Cites] J Mol Biol. 1988 Oct 20;203(4):971-83 [3210246.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(17):6498-502 [2549539.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1990 Jan 30;326(1235):179-87 [1968655.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1990 Jan 30;326(1235):285-97 [1968665.001]
  • [Cites] J Virol. 1990 Nov;64(11):5295-300 [2170673.001]
  • [Cites] EMBO J. 1991 Jan;10(1):143-51 [1846596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 May 1;88(9):3942-6 [1850841.001]
  • [Cites] J Virol. 1992 Jan;66(1):62-9 [1370095.001]
  • [Cites] J Gen Virol. 1991 Dec;72 ( Pt 12):3025-33 [1662694.001]
  • (PMID = 21416002.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033174
  •  go-up   go-down


36. Chuka-Okosa CM, Uche NJ, Kizor-Akaraiwe NN: Orbito-ocular neoplasms in Enugu, South-Eastern, Nigeria. West Afr J Med; 2008 Jul;27(3):144-7
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this era of HIV pandemic, an increase in the frequency of AIDS-related orbito-ocular neoplasms has also been reported.
  • METHODS: In a retrospective, non-comparative case series study the records of all the cases of orbito-ocular neoplasms seen in the Histopathology departments of the two tertiary multidisciplinary hospitals with major eye clinics in Enugu (ParkLane Specialist and University of Nigeria Teaching Hospitals) between January 2001 and August 2005 were analysed for types of tumours, frequency of occurrence, sex and age of patients.
  • Retinoblastoma was the most commonly occurring neoplasm accounting for 25.6% of all the tumours; followed by squamous cell carcinoma of the conjunctiva which was seen in 5 (11.6%) of cases.
  • Squamous papilloma and Burkitt's lymphoma each accounting for 9.3% of the tumours in the series were the third most commonly occurring ones.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Child. Child, Preschool. Female. Hospitals, Teaching / statistics & numerical data. Humans. Infant. Male. Middle Aged. Nigeria / epidemiology. Retinoblastoma / epidemiology. Retinoblastoma / pathology. Retrospective Studies. Sex Distribution. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19256317.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


37. Stebbing J, Mandalia S, Palmieri C, Nelson M, Gazzard B, Bower M: Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma. J Clin Oncol; 2005 Nov 20;23(33):8538-40; author reply 8540-1
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]
  • (PMID = 16293885.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


38. Mwanda WO, Whalen C, Remick SC: Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa. East Afr Med J; 2005 Sep;82(9 Suppl):S133-4
MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Burkitt Lymphoma / drug therapy. Epstein-Barr Virus Infections / drug therapy. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / drug therapy. Lymphoproliferative Disorders / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619688.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Grant] United States / PHS HHS / / A136219; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Kenya
  •  go-up   go-down


39. Jacobs SL, Rozenblit A: HIV-associated hypervascular primary Burkitt's lymphoma of the liver. Clin Radiol; 2006 May;61(5):453-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated hypervascular primary Burkitt's lymphoma of the liver.
  • [MeSH-major] Burkitt Lymphoma / radiography. Liver Neoplasms / radiography. Lymphoma, AIDS-Related / radiography

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16679121.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Ganguly S, Patel V, Dusing RW: Burkitt's lymphoma: conversion from lymphoma negative to lymphoma positive status over 2 months in a patient with acquired immunodeficiency syndrome (AIDS). Am J Clin Oncol; 2007 Dec;30(6):656-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma: conversion from lymphoma negative to lymphoma positive status over 2 months in a patient with acquired immunodeficiency syndrome (AIDS).
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091062.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Nyirenda M, Latham T, Glover S: Ward round--Recurrent anemia and infection in an HIV-positive woman. Burkitt's lymphoma. Malawi Med J; 2009 Jun;21(2):86, 88-9
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ward round--Recurrent anemia and infection in an HIV-positive woman. Burkitt's lymphoma.
  • [MeSH-major] Anemia / complications. Burkitt Lymphoma / complications. HIV Infections / complications. HIV Seropositivity / complications. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Lymphoma, AIDS-Related / therapy. Palliative Care / methods. Prognosis. Recurrence


42. Tanabe Y, Muraoka A, Ryu T, Saito T: [Acquired immunodeficiency syndrome associated with Burkitt's leukemia diagnosed by ileus]. Nihon Naika Gakkai Zasshi; 2008 Jan 10;97(1):150-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acquired immunodeficiency syndrome associated with Burkitt's leukemia diagnosed by ileus].
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Ileus / etiology. Lymphoma, AIDS-Related / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18283903.001).
  • [ISSN] 0021-5384
  • [Journal-full-title] Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
  • [ISO-abbreviation] Nippon Naika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Parekh S, Hebert T, Ratech H, Sparano J: Variable problems in lymphomas: CASE 3. Spontaneous regression of HIV-associated Burkitt's lymphoma of the cecum. J Clin Oncol; 2005 Nov 1;23(31):8116-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variable problems in lymphomas: CASE 3. Spontaneous regression of HIV-associated Burkitt's lymphoma of the cecum.
  • [MeSH-major] Burkitt Lymphoma / pathology. Cecal Neoplasms / pathology. Lymphoma, AIDS-Related / pathology. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Feb 20;23(6):1152-60 [15718311.001]
  • (PMID = 16258111.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


44. Spina M, Simonelli C, Talamini R, Tirelli U: Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era. J Clin Oncol; 2005 Nov 1;23(31):8132-3; author reply 8133-4
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2005 Jul 1;23(19):4430-8 [15883411.001]
  • (PMID = 16258119.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement